Oral vinorelbine as monotherapy in treatment of advanced breast cancer. Literature review
https://doi.org/10.18027/2224-5057-2016-2-43-48
Abstract
The aim of the treatment of advanced breast cancer, in addition to increasing of overall survival and increasing of the duration of remission, is to improve the quality of life of such patients. To date, the determining factor in the treatment of patients with advanced breast cancer is a biological type of the tumor, and the approach to the choice of chemotherapy should be individualized taking into account many factors, including the duration of progression-free survival, already provided treatment, the biology of the tumor, presence of visceral metastases, the nature of comorbidity and the patient’s wishes. All these factors need to be considered when discussing the options for subsequent chemotherapy in patients with disease progression after anthracyclines and/or taxanes.
References
1. Cardoso F, Senkus-Konefka E, Fallowfield L, et al. Locallyrecurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl. 5): v15–9.
2. Aapro M, Finek J. Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results. Cancer Treat Rev. 2012 Apr;38(2):120–6. doi: 10.1016/j.ctrv.2011.05.005. Epub 2011 Jul 13. Review.
3. Pajk B, Cufer T, Canney P, et al. Anti-tumor activit y of capecitabine and vinorelbine in patients with anthracycline and taxane-pretreated metastatic breast cancer: findings from the EORTC10001 randomized phase II trial. Breast 2008;17:180–5.
4. Twelves C, Gollins S, Grieve R et al. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 2006 17: 239–245.
5. Liu G, Franssen E, Fitch MI et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110–115.
6. Wojtacki J, Wiraszka R, Rolka-Stempniewicz G et al. Breast cancer patients’ preferences for oral versus intravenous second-line anticancer therapy. Eur J Cancer 2006; 4 (Suppl 2): 159 (Abstr 381).
7. Fallowfield L, Atkins L, Catt S et al. Patients’ preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 2006; 17: 205–210.
8. Findlay M, von Minckwitz G, Wardley A. Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol. 2008 Feb;19(2):212–22. Epub 2007 Nov 15. Review.
9. Fellous A, Ohayon R, Vacassin T, et al. Biochemical effects of vinorelbine on tubulin and associated proteins. Semin Oncol 1989;16(Suppl. 4).
10. Cros S, Wright M, Morimoto M, et al. Experimental antitumor activity of vinorelbine. Semin Oncol 1989;16(Suppl. 4).
11. Goa K, Faulds D. Vinorelbine: a review of its pharmacological properties and clinical use in cancer chemotherapy. Drug Aging 1994;5(3):200–34.
12. Gebbia V, Puozzo C. Expert Opin Drug Saf. 2005 Sep;4(5):915–28. Review.
13. Fumoleau P, Delgado DM, Delozier T et al. Phase II trial of weekly intravenous vinorelbine in firstline advanced breast cancer chemotherapy. J. Clin. Oncol. (1993) 11:1245–1252.
14. Garcia-Conde J, Lluch L, Martin M et al. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann. Oncol. (1994) 5(9):854–857.
15. G.G. Steger, A. Dominguez, O. Switsers, N. Dobrovolskaya, F. Giotta, I. Glogowska, N. Tubiana-Mathieu, M. Pecherstorfer, A. Ardizzoia, P. Bougnoux, M. Blasinska, C. Veyret, S. Garcia, J. Dorca, C. Marth, G. Manikhas, M. Benasso, S. Protsenko G. Villanova, E. Espinosa. Phase II study evaluating oral vinorelbine as a single-agent as first-line chemotherapy for metastatic breast cancer patients with bone metastases (norbreast‑228 trial): first efficacy results. ESMO, 2014.
16. Bonneterre J, Chevalier B, Focan C, Mauriac L, Piccart M. Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC). Ann. Oncol. (2001) 12(12):1683–1691.
17. Winer E, Chu L, Spicer DV. Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer. Semin. Oncol. (1995) 22(2 Suppl. 5):72–78.
18. Freyer G, Delozier T, Lichinister M et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J. Clin. Oncol. (2003) 21(1):35–40.
19. Amadori D, Koralewski P, Tekiela A. Efficacy and safety of navelbine oral (NVBO) in first line metastatic breast cancer (MBC). Eur. J. Cancer (2001) 37:22 Abstract.
20. Pluschnig U, Bartsch R, Gampenrieder S, et al. Oral vinorelbine in metastatic breast cancer: the Vienna experience. Ann Oncol 2008;19(Suppl. 8) (abstract 160). Blancas I, Morales S, Diaz N, et al. Efficacy and safety of oral vinorelbine in first or second-line metastatic breast cancer. J Clin Oncol 2010;28:15S (abstract 1090).
21. Mansour M, Haddad N. Phase II study of single agent oral vinorelbine as a first line chemotherapy for metastatic breast cancer patients previously treated with adjuvant anthracyclines and/or taxanes. Proc 21st International Congress on Anti-Cancer Treatment, 2010 (abstract 627).
Review
For citations:
Khisamov A.A. Oral vinorelbine as monotherapy in treatment of advanced breast cancer. Literature review. Malignant tumours. 2016;(2):43-48. (In Russ.) https://doi.org/10.18027/2224-5057-2016-2-43-48
Views:
714
Email this article 